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Backgroud: The effect of hCG priming on oocyte maturation and subsequently outcome in IVM cycles has
remained a debated issue. A randomized controlled study was performed to investigate whether or not hCG
priming prior to oocyte aspiration can improve the developmental competence of immature oocytes from
unstimulated ovaries in women with polycystic ovarian syndrome (PCOS).
Methods: Eighty two patients with PCOS underwent IVM cycles. Each patient was randomly assigned to the
hCG-primed (10,000 IU) or non-primed groups 36–38 hours before oocyte retrieval depending on the computerized
random table. After the oocytes had in vitro matured, fertilization, culture and embryo transfer were performed.
Results: The average number of cumulus-oocyte complexes (COCs) recovered was 13.80 and 14.35 in the hCG-
primed and non-primed groups, respectively (p> 0.05). The maturation rate of COCs was significantly improved
in the hCG-primed group (55.43% vs. 42.29%; p< 0.05). The fertilization and cleavage rates were comparable
between the groups. The hCG-primed and non-primed groups did not differ with respect to the clinical pregnancy
(37.50% vs. 50.00%), live birth (22.50% vs. 30.95%), and implantation rates (32.86% vs. 32.56%). The pregnancy
losses was 6 (40.00%) of 15 clinical pregnancies in the hCG-primed group, and 8 (38.10%) of 21 clinical pregnancies
in the non-primed group.
Conclusions: While a significant improvement in the nuclear maturation rate of immature oocytes was observed
in hCG-primed IVM cycles with PCOS patients, the use of hCG prior to oocyte retrieval did not improve the
subsequent embryo developmental competence. The high rate of pregnancy loss in IVM cycles should receive
more attention.
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Polycystic ovarian syndrome (PCOS) is a common endo-
crine disorder characterized by ovarian hyperandrogen-
ism, insulin resistance, and paracrine dysregulation of
follicle development [1,2]. PCOS has a negative effect on
female fecundity. The estimated prevalence of PCOS is
5%–10%, as reported in population-based studies [3].
Trounson et al. [4] described the first pregnancy and
delivery of a healthy baby after in vitro maturation* Correspondence: jie.qiao@263.net
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reproduction in any medium, provided the or(IVM) of immature oocytes obtained from a patient with
PCOS. Over the next decade, immature oocyte retrieval
followed by IVM has become a widespread treatment
for infertile women with PCOS because there are
numerous antral follicles within the ovaries in this group
of patients. Compared with ovary-stimulated in vitro
fertilization (IVF), the major advantages of IVM include
avoidance of the risk of ovarian hyperstimulation syn-
drome, reduced cost, and simplification of treatment.
Nevertheless, IVM has not been adopted as a main-
stream method in infertility treatment even though rea-
sonable results have been reported by some clinics [5-7].
The explanation for this is the fact that IVM tends to
have a lower rate of live births per treatment compared
with conventional IVF. A number of factors might leadLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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synchronization of oocyte nuclear and cytoplasmic mat-
uration, suboptimal culture conditions, an endocrine
disturbance and suboptimal timing of insemination [8-11].
Gonadotropins play an important role in the regula-
tion of oocyte growth and maturation. In order to mimic
the pre-ovulatory luteinizing hormone (LH) surge in
spontaneous menstrual cycles, human chorionic gonado-
tropin (hCG) is routinely administered at a dose of
5000–10000 IU as a surrogate for LH at the end of fol-
licular stimulation to trigger the resumption of meiosis
and nuclear maturation of oocytes using IVF technology.
The traditional application of hCG has shown to be
highly successful and valuable tools in the treatment of
infertility for> 4 decades [12]. However, the effect of
hCG priming on oocyte maturation and developmental
competence in IVM cycles has remained a contested
issue. Chian and colleagues [13] demonstrated that hCG
priming could speed up the maturation time of oocytes
in women with PCOS. Subsequently, the results of a
multicentre study by the same investigators provided
further support for this initial finding by reporting preg-
nancy rates of 30%–35% in hCG-treated IVM cycles in
patients with PCO and PCOS [5]. However, similar stud-
ies did not demonstrate a beneficial effect of hCG prim-
ing [6,14]. Among the many reports [5,6,9-11,13,14]
involving pregnancy rates after IVM with gonadotropin
priming, there is limited data generated from rando-
mized controlled clinical studies [13]. Therefore, the
present study was designed according to a randomized
controlled paradigm to demonstrate whether or not
hCG priming prior to oocyte aspiration involving IVM
oocytes from unstimulated women with PCOS can
improve embryonic developmental competence and
yield respective favorable clinical outcomes.
Methods
Patients
This protocol was approved by the Ethics Committee
of the Peking University (the registration number:
2006FC001). Between January 2007 and December 2008,
82 patients with PCOS underwent IVM cycles at the Re-
productive Centre of Peking University Third Hospital.
These patients consistently met the Rotterdam ESHRE/
ASRM consensus criteria for the diagnosis of PCOS [1].
The mean age of the patients was 30.2 years (range, 24–
39 years). All patients had oligo-anovulation and pre-
sented with irregular menstrual cycles (35–90 days) or
amenorrhoea. Written informed consent was obtained
from each patient before undergoing treatment.
In vitro maturation protocol
To initiate the IVM treatment cycle in anovulatory
patients, the patients received intramuscular injectionsof progesterone (Progesterone Injection; Xianju Phar-
macy, Zhejiang, China) 40 mg daily for 7 days. A with-
drawal bleed occurred within 7 days after the last dose.
A baseline ultrasound scan was obtained on day 2 or 3
following the onset of menstrual bleeding to ensure that
no ovarian cysts were present. For the purpose of the
current study, women were randomly allocated to one of
two groups depending on the computerized random
table on the day of the first baseline ultrasound scan,
as follows: primed with 10,000 IU hCG; or no priming.
The patients and the embryologist were blind to the
random results. Transvaginal ultrasound scans were
repeated on days 6–8 to exclude the development of a
dominant follicle. Oocyte retrieval was scheduled once
the endometrium had reached at least 6 mm in thickness
and there was no follicle larger than 10 mm. According
the random results, the hCG (Profasi, 10000 IU, Serono,
Aubonne, Switzerland) was given subcutaneously to
patients in the hCG-primed group. Immature oocyte
collection was performed 36–38 h after hCG priming;
while oocyte retrieval was undertaken directly in the
non-primed group without hCG injection.
Transvaginal ultrasound–guided collection of oocytes
was performed with a specially designed 19 G single-
lumen aspiration needle (K-OPS-7035-REH-ET; Cook,
Queensland, Australia). For aspiration, the suction pres-
sure was reduced to 80 mm Hg. Follicular aspirates were
collected in 10 mL culture tubes and filtered through a
cell strainer (Cell Strainer 352350, 70 μm nylon; Falcon,
MA, USA). After filtering, the collected aspirates were
rinsed with pre-warmed DPBS (Sigma-Aldrich, St. Louis,
MO, USA) and transferred to a 100x15 mm Petri dish
(Nunc, Roskilde, Denmark) to search for cumulus-oocyte
complexes (COCs) under a stereomicroscope. All COCs
were then transferred into IVM oocyte medium (IVM
media kit; Sage, CT, USA) supplemented with 0.075 IU/
mL FSH and 0.075 IU/mL LH (Menopur; Ferring, Kiel,
Germany) for maturation in 5% CO2 incubator at 37°C
with satured humidty. After 28–32 h of culture, the
oocytes were denuded of cumulus cells for observing the
presence of a first polar body extrusion. All the meta-
phase II (MII) oocytes were inseminated by means of
intracytoplasmic sperm injection (ICSI).
Fertilization was considered normal when two pro-
nuclei were present between 16 and 18 h after ICSI.
Only normally fertilized oocytes were further considered
for embryo transfer or cryopreservation. All zygotes
were cultured in cleavage medium (G-M, LifeGlobal,
CT, USA) supplemented with 10% synthetic serum sub-
stitute (SSS; Irvine Scientific, Santa Ana, CA, USA) up
to day 3 after ICSI. Prior to transfer or cryopreservation,
embryonic development was assessed according to the
developmental stage and degree of cytoplasmic frag-
mentation. Two or three of the morphologically best
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numerary good-quality embryos (4–8 cells, ≤30% frag-
mentation, even size) were cryopreserved.
Endometrial preparation and luteal support
For preparation of the endometrium, patients were given
oestradiol valerate (Progynova, 6 mg orally; Schering,
Berlin, Germany) starting on the day of oocyte retrieval.
Luteal support was provided with 60 mg of progesterone
(Progesterone Injection, Xianju Pharmacy, Zhejiang,
China) intramuscularly daily starting from the day of
ICSI. Both medications were continued until either a
pregnancy test was negative or a positive fetal heartbeat
was observed.
The serum hCG concentration was determined 14 days
after embryo transfer (ET) and again 1 week later. Clin-
ical pregnancy was defined as the presence of an intra-
uterine gestational sac on ultrasound examination on
day 35 after ET. The implantation rate was calculated as
the number of gestational sacs identified on ultrasound
per number of transferred embryos.
Statistical analysis
Statistical analysis was performed using SPSS 10.0. Dif-
ferences were considered significant at p< 0.05. For
comparison of the mean variables, Student’s t-test was
used. A χ2 analysis was used between group comparisons
of reproductive outcomes, including implantation, clin-
ical pregnancy, and birth rates.
Results
Basic patient characteristics, including mean female age,
body mass index (BMI), and baseline FSH did not differ
between the hCG-primed (40 women) and the non-
primed groups (42 women; Table 1).
The average number of COCs recovered was 13.80








age (years) 30.03 ± 3.65 30.33 ± 3.71 ns
BMI (kg/m2) 24.93 ± 4.94 25.37 ± 5.75 ns
No. of primary
infertility (%)
34 (85.00) 37 (88.10) ns
Basal FSH (IU/mL) 5.57 ± 1.76 6.08 ± 1.66 ns
Antral follicle count 22.60 ± 5.93 22.76 ± 5.99 ns
No. of anovulatory (%) 36 (90.00) 34 (80.95) ns
No. of patients with biochemical
hyperandrogenism (%)
25 (62.5) 20 (47.62) nsrespectively (p> 0.05). However, the COCs had a differ-
ent appearance between the two groups. All COCs in
the non-primed group had a compacted or sparse
cumulus (Figure 1), while nearly 35% of immature
oocytes in the hCG-primed group were with a dispersed
cumulus (Figure 2). The maturation rate of COCs was
significantly improved in the hCG-primed group
(55.43% vs. 42.29%; p< 0.05). However, the fertilization
and cleavage rates were comparable between the hCG-
primed and non-primed groups (Table 2).
Good-quality embryos (4–8 cells, ≤30% fragmentation)
were transferred on day 3 after ICSI. Embryo transfers
were cancelled for 6 cases in the hCG-primed group
because of a failure of fertilization (n = 3) or poor
embryo development (n = 3). For 2 cases in the non-
primed group, transfers did not take place because of a
lack of matured oocytes acquired in 32 h (n = 1) or poor
embryo quality (n = 1). The details of the pregnancy out-
comes are shown in Table 2. There was no significant
difference in the clinical pregnancy, live birth, and
implantation rates between the two groups. The number
of late fetal losses was 3 in each group, including one
termination for a congenital cardiac abnormality in the
non-primed group and one for abnormal neurologic
development in the hCG-primed group.
As of October 2010, fresh embryo transfers after IVM
resulted in the births of 28 infants (15 boys and 13 girls)
in 2 groups. There were 9 delivers and 13 babies (5 sin-
gletons and 4 twins) in hCG-primed group, meanwhile
13 delivers and 15 babies (11 singletons and 2 twins) in
non-primed group. The details of the pregnancies are
shown in Table 2. In addition, one singleton baby in the
non-primed group was born through 16 frozen-thawed
embryo transfers, including 10 cases in hCG-primed and
6 cases in non-primed group.Figure 1 Immature oocytes with compacted or sparse cumulus
in the non hCG-primed group.
Table 2 In vitro maturation outcome of PCOS women






No. of oocyte retrieval
cycles
40 42
No. of oocytes retrieved
Total (range) 552 (1–50) 603(1–47)
Mean 13.80 14.35 ns
No. of oocytes matured
at 32 h
Total (range) 306 (1–21) 255 (0–18)
Mean 7.65 6.07
Maturation rate (%) 55.43 42.29 0.000
No. of oocytes fertilized (%) 194 (63.40) 167 (65.49) ns
No. of oocytes cleaved (%) 192 (98.97) 166 (99.10) ns
Cycles with embryo
transfer (%)
34 (85.0) 40 (95.24) ns
No. of embryos transferred
(mean)
70 (2.06) 86 (2.15) ns
No. of clinical pregnancies 15 21
Clinical pregnancy rate
per OR a (%)
37.50 50.00 ns
Clinical pregnancy rate




23 (32.86) 28 (32.56) ns
No. of live birth (% per OR) 9 (22.50) 13 (30.95) ns
Singleton 5 11
Twins 4 2
No. of infants 13 15







No. of cycles with embryo
freezing
19 (47.50) 13 (30.95) ns
a OR oocyte retrieval.
b ET embryo transfer.
c Miscarriage was defined as pregnancy loss after ultrasonographic evidence
of an intrauterine pregnancy.
d Late miscarriage was defined as pregnancy loss between 12 and 28 weeks of
gestation, which includes any termination of pregnancy after diagnosis of a
congenital abnormality.
Figure 2 Immature oocytes with dispersed cumulus in the hCG-
primed group.
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It is known that LH receptors are expressed by granu-
losa cells in the late stages of follicle development
when antral ovarian follicle diameter increases beyond
approximately 10 mm [15]. Therefore, queries about the
hCG effect on the IVM cycles in which most follicle dia-
meters were< 10 mm continue. The rationale for hCG
priming in IVM cycles in women with PCOS was based
on the finding that in vivo administration of hCG
enhances the nuclear maturation of oocytes [13],
although the underlying mechanism is unclear. Our
randomized controlled study demonstrated also an
improved maturation rate of COCs with hCG-priming.
LH receptors in theca cells may be a partially explan-
ation for that. It is well known that theca cells express
LH receptors from the secondary follicle stage, and LH
is capable of stimulating androgen substrate production.
Androgens can be transformed into estrogens through
the action of the aromatase system, and then estrogens
in turn play a role in improving follicle and oocyte
maturity. Another explanation may due to the prema-
turely expression of LH receptor in granulosa cells from
polycystic ovaries [16]. Indeed, Yang et al. [17] observed
LH receptor expression in cumulus cells of oocytes gen-
erated from IVM cycles of PCOS patients. Although the
follicle diameter was less than 10 mm, the granulosa
cells become receptive to hCG stimulation; hCG was
then capable of exerting its actions, including initiating a
cascade of molecular events, stimulation of steroid pro-
duction [18] and extracellular matrix production, known
as cumulus expansion or mucification [19] in the COCs.
In fact, we observed that nearly one-third of COCs have
dispersed cumulus cells in the hCG-primed group, while
all COCs were compact or sparse cumulus cells in the
non-hCG primed group. This is consistent with LHsurge that, in vivo, induces the cumulus expansion. So
on, the hCG treatment “found” some receptors to pro-
duces a mimetic action similar to LH surge.The imma-
ture oocytes with dispersed cumulus cells at the time of
collection have a high nuclear maturation rate among
PCOS patients [20]. Some reports indicated that hCG
priming during IVM cycles in women without PCO and
regular menstrual cycles had not been shown to have a
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oocytes [6,11,14]. The discrepancy in the hCG priming ef-
fect on COCs maturation in IVM cycles may be explained
by the selection differences amongst patients. The abnor-
mally premature expression of LH receptor in granulosa
cells was only found from polycystic ovaries [16], and
then hCG can exert the action through the LH receptor.
Complete maturation of oocyte is essential for the devel-
opmental competence of embryos. Non-synchronization
of oocyte nuclear and cytoplasmic maturation was consid-
ered to be a major reason for poor developmental compe-
tence of IVM oocytes [21,22]. hCG administration in vivo
can fasten the nuclear maturation process, as discussed
above, while the effect on cytoplasmic maturation was
unclear. Cytoplasmic maturation was important in prep-
aration for fertilization and early embryo development,
the inadequacy tends to present later in development as
impaired embryo cleavage or implantation failure. We
found no substantial improvement in the developmental
competence of oocytes in the current study, although
hCG priming before oocyte retrieval promoted oocyte
nuclear maturation. The clinical endpoints (pregnancy
and live birth rates), of the primed and non-primed
groups showed no significant differences. Similarly, an
improved maturation rate was not reflected in the preg-
nancy outcomes in the report by Chian et al. [13], which
favored hCG priming first. Anttila et al. [6] did not find
a beneficial effect of hCG priming on the number of
oocytes collected, and the fertilization or cleavage rates
compared with non-primed patients undergoing IVM.
The lack of effect of hCG priming on clinical indices
could reflect that hCG priming was not enough to
improve the cytoplasm maturation. Indeed, how to
optimize the clinical regimen and embryo culture condi-
tions to achieve the best synchronized oocyte nuclear and
cytoplasmic maturation for IVM merits further research.
Another important reason which limited the wide-
spread uptake of IVM was the question of safety, includ-
ing pregnancy loss, congenital abnormality and post-natal
outcomes. The miscarriage rate in IVM pregnancies
varies between 25% and 57% [23]. This could be regarded
as high, but conclusions are difficult to draw as the data
come from observational studies without adequate con-
trols. In our investigation, the miscarriage rate of IVM
was nearly 40% and higher than conventional IVF/ICSI
(15%) during the same time period in our clinic, whether
with or without hCG priming. It was suggested that hCG
priming was not useful to decrease pregnancy loss. The
basis for high pregnancy loss of IVM in PCOS has yet
to be investigated. Possible explanations include unknown
effects from special patient population, poorer embryo
quality, or suboptimal endometrial preparation. Some
investigators have observed that the clinical miscarri-
age rate in IVM pregnancies is not higher than IVFpregnancies when controlled for patient characteristics
[24,25]. Buckett et al. [24] proposed that a higher rate of
pregnancy losses after IVM is related to PCOS rather
than the IVM procedure itself. On the other hand, Con-
focal microscopic analysis of the spindle and chromosome
structure of human IVM oocytes have shown that there is
a higher frequency of abnormal meiotic spindle and
chromosomal alignment than in vivo matured oocytes
[26]. Additional studies are needed to clarify the roles of
IVM and PCOS in the observed miscarriage cases to fur-
ther our understanding in helping infertile women of
PCOS undergoing IVM. It is worth noting that there was
one case of pregnancy termination because of congenital
malformations in each group. In our study, no congenital
defect had been found in the 28 delivered babies at birth.
Due to the very low numbers of IVM infants in present
and other study, it is impossible at present to determine
accurately whether IVM is associated with an increased
risk of congenital birth defects. Careful long-term follow-
up studies need to be conducted.
Conclusions
In conclusion, this randomized controlled study showed
a significant improvement in the nuclear maturation of
immature oocytes in hCG-primed IVM cycles in PCOS
patients, while the respective embryo competence improve-
ment was not observed through the use of hCG prior to
oocyte retrieval. Acceptable live birth results can be
achieved in PCOS patients in the hCG-primed and non-
primed groups. The high number of pregnancy losses
registered in the present study call for caution in clinical
practice with respect to IVM. hCG priming was not useful
in decreasing the miscarriage rate. How to optimize the
clinical regimen and embryo culture conditions to improve
oocyte development competence needs further study.
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